A-Z™ AD Drug Discovery Platform
For more than 10 years, Creative Biolabs has provided comprehensive customized solutions to customers worldwide. With state-of-the-art technology and innovative platforms, we deliver the highest quality service using expertise and personalized solutions.
Overview
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss and personality changes that can lead to dementia. AD animal models may be very useful for studying the pathophysiology of disease and for testing new therapies in preclinical studies. When choosing a model, researchers should consider various factors that may influence the phenotype. They should also consider the timing of the test/treatment animals, as the age at which certain aspects of AD pathology occur in each model is different. A combination of animal and sequential testing in a model system may be more predictive of human efficacy and provide more insight into the range of effects of this agent.
Biomarkers in AD Drug Development
There are five primary types of biomarkers relevant to AD drug development. We offer AD biomarker assays.
- Brain imaging
- Electrophysiologic Measures
- Measurement of prespecified analytes in plasma and cerebrospinal fluid (CSF)
- "Omics" platform with microarray and spectrometry for the determination of multiple genes, proteins, lipids, and metabolites
- Genetics
Models and Assays for AD Preclinical Drug Discovery at Creative Biolabs
In vitro tools have particular advantages in assessing some variables of drug metabolism, even when compared to in vivo models. In vitro tools allow for precise cellular exposure to a given drug. 3D culture models are a promising technique to develop more realistic in vitro disease models for CNS drug research and development. 3D in vitro models obtained using PSC-derived cells would provide a realistic platform for toxicity assessments and drug screening applications.
Fig.1 Platform for AD drug screening in a 3D human neural cell culture model of AD.
Transgenic and non-transgenic animal models develop synaptic and memory deficits. They are useful for AD drug discovery. Most Tg models are mice, while non-Tg models can also be rats, monkeys, and dogs.
a. Tg models of AD, consisting of single or multi-Tg animals overexpressing APP, PS, and/or Tau mutations.
Mice overexpression of APP (K670N: M671L) and PS1 (M146L) have been widely used to better understand the pathogenic mechanisms of synaptic dysfunction and memory loss in AD and to validate novel therapeutic approaches. These mice presented a robust age Aβ dependent deposition in plaques preceded by an increase of soluble Aβ40 and Aβ42.
b. Non-Tg models obtained by toxins injection in the brain, including direct injection of Aβ or tau, and models of aging.
Non-Tg models for the study of AD have mainly been obtained by injecting Aβ or tau directly into the brain through intraventricular or hippocampal injection. These models allow:
- Investigate Aβ the effects of tau in animals for which Tg models are not available.
- Exclude the confounding effects of overexpression of APP and its fragments.
- Investigate the different roles of Aβ and tau species (monomers vs. oligomers vs. insoluble) at different concentrations.
- To study the difference between acute and chronic administration.
- Clarify aspects of the molecular mechanisms underlying Aβ and tau pathology.
Creative Biolabs is a preclinical contract research organization that provides customized services for AD drug discovery. We are unique in that our scientists can solve problems creatively. Please do not hesitate to contact us and our enthusiastic scientists will discuss it with you in detail.
- NeuroMab™ Anti-Integrin αvβ8 BBB Shuttle Antibody(NRZP-1222-ZP1218) (Cat#: NRZP-1222-ZP1218)
- NeuroMab™ Anti-pTau Antibody(NRP-0422-P1719) (Cat#: NRP-0422-P1719)
- NeuroMab™ Anti-Amyloid Beta 1-15 Antibody(NRP-0422-P867) (Cat#: NRP-0422-P867)
- NeuroMab™ Anti-GD2 Antibody(NRZP-1222-ZP767) (Cat#: NRZP-1222-ZP767)
- NeuroMab™ Anti-TREM2 BBB Shuttle Antibody(NRZP-1022-ZP4114) (Cat#: NRZP-1022-ZP4114)
- NeuroMab™ Anti-TREM2 Antibody(NRP-0422-P792) (Cat#: NRP-0422-P792)
- NeuroMab™ Anti-Tau Antibody(NRP-0422-P2275) (Cat#: NRP-0422-P2275)
- NeuroMab™ Anti-CD32b Antibody(NRP-0422-P1803) (Cat#: NRP-0422-P1803)
- NeuroMab™ Anti-FGFR1 Antibody(NRP-0422-P1244) (Cat#: NRP-0422-P1244)
- NeuroMab™ Mouse Anti-LRP1 Monoclonal Antibody (CBP3363) (Cat#: NAB-0720-Z6479)
- Rat Immortalized Retinal Muller Cell Line rMC-1 (Cat#: NCL-2106-S93)
- Human Brain Microvascular Endothelial Cells (Cat#: NCL-2103-P133)
- iNeu™ Human Midbrain Dopaminergic Neurons (Cat#: NCL-21P6-003)
- Rat Olfactory Ensheathing Cells (Cat#: NRZP-1122-ZP162)
- Human Blood Brain Barrier Model (Cat#: NCL-2103-P187)
- Human Hippocampal Neuron Cells HPPNCs (Cat#: NCL2110P106)
- Rat Muller Cell (Cat#: NCL2110P040)
- Mouse Microglia Cell Line BV-2, Immortalized (Cat#: NCL2110P153)
- iNeu™ Human Sensory Neurons (Cat#: NCL-2103-P62)
- iNeu™ Human Neural Stem Cell Line (Cat#: NCL200552ZP)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Dextran, NHS Activated, 40 kDa (Cat#: NRZP-0722-ZP124)
- pAAV-EF1a-DIO-EGFP-WPRE (Cat#: NTA-2012AD-P285)
- Dextran-CYanine5.5 (Cat#: NTA-2011-ZP118)
- Dextran, Cy5 Labeled, 2000 kDa (Cat#: NRZP-0722-ZP22)
- AAV2/9-hEF1a-DIO-mCherry-P2A-TetTox-WPRE-pA (Cat#: NTA-2012-ZP268)
- Dextran-FITC (Cat#: NTA-2011-ZP110)
- pAAV-syn-jGCaMP8f-WPRE (Cat#: NTA-2106-P061)
- AAV2/9-hSyn-Flpo-EGFP-WPRE-pA (Cat#: NTA-2012-ZP149)
- PRV-CAG-EGFP (Cat#: NTA-2011-ZP14)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- App Rat amyloid beta (A4) precursor protein (App)(NM_019288) ORF clone, Untagged (Cat#: NEP-0421-R0053)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroPro™ Anti-IDS BBB Shuttle Protein (Cat#: NRZP-0423-ZP503)
- NeuroPro™ Anti-SGSH BBB Shuttle Protein (Cat#: NRZP-0423-ZP505)
- NeuroPro™ Anti-ASA BBB Shuttle Protein (Cat#: NRZP-0423-ZP504)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP509)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP501)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP502)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)